Market Research Hub

Hepatitis C Pipeline Assessment and Therapeutic Landscape Reviewed for H1 2017

Latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C Pipeline Review, H1 2017, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.


Albany, NY -- (SBWIRE) -- 05/22/2017 -- Market Research Hub (MRH) has recently highlighted the pipeline landscape of Hepatitis C therapeutics in a new report added to its repository, with a title of "Hepatitis C - Pipeline Review, H1 2017". The main purpose of this study is to provide an assessment of the various pipeline therapeutics for the disease. For a competitive study, the research has listed key companies functioning in the market, focusing on their research and development efforts, adoption to changing trends, and their efforts to discover new therapeutics for Hepatitis C.

Request Free Sample Report :

According to the study, the incidence of hepatitis C infection among the global population is increasing. More than 82 % of those who are infected will progress to chronic liver disease. It is supposed that there are, at present, more than 4.5 million people in the United States that are infected with hepatitis C, and more than 200 million around the world. This is mainly caused by sharing needles, unsterilized medical equipment, and blood transfusion from infected mother to newborn baby. In hepatitis C infection treatment, there are around 2300 molecules are in pipeline studies. Various companies are getting involved in the development of hepatitis C treatment medication. This would lead to development of new products, which eventually drives the market.

In the first part, the report presents the Hepatitis C overview. Hepatitis C is a viral infection that causes liver inflammation, sometimes leading to severe liver damage. The critical stage of infection may display symptoms including fever, dark urine, abdominal pain, and yellow-tinged skin occurrence. The influencing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Acute Hepatitis C may not be treated because symptoms are usually mild or absent, and hepatitis C is therefore often not identified. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Moving further, the analysts have conducted an assessment of Hepatitis C therapeutics on the basis of molecule type, stage of development, drug target, route of administration, and mechanism of action. With the deep analysis on its therapeutic development, this pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective strategies to gain competitive advantage.

Browse Full Report with TOC -

The report further analyzes key player in the therapeutic market and features their dormant and discontinued projects. Some of the major companies operating in the therapeutic development include 3-V Biosciences Inc, AbbVie Inc, Beijing Kawin Technology Share-Holding Co. Ltd., AIMM Therapeutics BV, Biocad, GinkgoPharma Co. Ltd., Aviragen Therapeutics Inc, Beta Pharma Inc, Merck & Co Inc, GlaxoSmithKline Plc, WhanIn Pharmaceutical Co. Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc, Zylacta Corp and others.

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email :
Website :